CLOs on the Move

Aegis Living

www.aegisliving.com

 
Áegis Living is a national leader in assisted living and memory care. Providing the finest in senior lifestyle and living options, “We`re the people who make life better” emphasizes health, quality of life, well-being and community. Founded in 1997 and headquartered in Redmond, WA, privately-held Áegis Living operates 30 communities in Washington, California and Nevada, with five currently in development.
  • Number of Employees: 100-250
  • Annual Revenue: $100-250 Million

Executives

Name Title Contact Details
Ana De La Cerda
VP Regulatory Compliance Profile

Similar Companies

Quality Medical Evaluations

Quality Medical Evaluations is a Westborough, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Magpie Healthcare

Magpie Healthcare is a Denver, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

M and S Technologies

M & S Technologies is a Skokie, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Balboa Park

Balboa Park is a San Diego must-see, just minutes from downtown. The Park is home to 15 major museums, several performing arts venues, lovely gardens and many other cultural and recreational attractions–including the San Diego Zoo. Step into the beauty...

Foghorn Therapeutics

More than 20,000 genes make us human. Genes control critical aspects of health and disease — but what controls our genes? Foghorn® Therapeutics ($FHTX) is developing therapies based on a system that directs which genes our cells express, and when, where, and in what order. By manipulating this system with our unique Gene Traffic Control™ platform, Foghorn will change how genes turn “on” and “off.” Unlike approaches that edit genes, this novel way of thinking will alter what our DNA has in store for us—and rewrite destiny for millions of people living with disease. With Gene Traffic Control™ Foghorn is pioneering a new, major class of drug targets to develop unprecedented therapies for cancer and other serious diseases. We have already validated multiple targets, are in the process of developing drug candidates in multiple types of cancer and are beginning to explore other diseases.